Xarb 150 Tablet contains Irbesartan 150 mg, an angiotensin II receptor antagonist used primarily for the management of hypertension and diabetic nephropathy in patients with type 2 diabetes. By selectively blocking the binding of angiotensin II to the AT1 receptor, Irbesartan inhibits vasoconstriction and aldosterone secretion, resulting in vasodilation and reduced blood pressure. This mechanism helps to decrease the workload on the heart and prevent complications associated with high blood pressure, such as stroke, myocardial infarction, and renal impairment. Xarb 150 is indicated for the treatment of essential hypertension and for slowing the progression of renal disease in hypertensive patients with type 2 diabetes and microalbuminuria or proteinuria. The tablet is administered orally, typically once daily, with or without food, and dosage adjustments may be necessary based on clinical response and renal function. Common adverse effects include dizziness, fatigue, and gastrointestinal disturbances, while serious side effects are rare but may include hyperkalemia and renal dysfunction. Xarb 150 should be used cautiously in patients with impaired renal or hepatic function and is contraindicated during pregnancy due to potential fetal harm. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy to ensure safety and efficacy.